Towa Pharmaceutical plans to issue up to 20 billion yen of preferred shares through third-party allotment on May 21, 2026, to fund capital expenditures and collaborations. They will also execute amendments to the articles of incorporation and reduce capital to strengthen their financial base.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4553-20260521-01.pdf","jir_short_summary":"Towa Pharmaceutical plans to issue up to 20 billion yen of preferred shares through third-party allotment on May 21, 2026, to fund capital expenditures and collaborations. They will also execute amendments to the articles of incorporation and reduce capital to strengthen their financial base.","jir_summary":"### Overview of Capital Policy\nTowa Pharmaceutical decided to issue up to 20 billion yen of preferred shares through a board resolution on May 21, 2026. They will also reduce capital by 5 billion yen and amend the articles of incorporation to allocate funds for capital expenditures and collaboration projects. This aims to support business growth and strengthen the financial foundation.\n\n### Future Outlook and Shareholder Impact\nThe funds raised will be used to expand manufacturing lines and invest in collaborations, contributing to business expansion and the development of a stable supply system. The capital reduction will not affect net assets, and there is likely to be no direct change in shareholders' voting rights or ownership ratios.","jir_financial_highlights":"Funding Amount: Up to 20 billion yen (New funding)\nDecrease in Capital: 50 billion yen (Decrease)\nNumber of Issued Shares (First A-type Preferred Shares): 10,000 shares (New issuance)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #CapitalPolicy, #JapanStocks","jir_key_figures":"Funding Amount: Up to 20 billion yen\nDecrease in Capital: 50 billion yen\nNumber of Issued Shares (First A-type Preferred Shares): 10,000 shares","jir_meta_title":"\u3010Towa Pharmaceutical\u3011Capital Enhancement and Capital Expenditure | May 2026","jir_meta_description":"Towa Pharmaceutical plans to issue up to 20 billion yen of shares and reduce capital in May 2026. This IR material highlights their efforts to expand through investments and collaborations.","jir_og_title":"Towa Pharmaceutical's Capital Policy and Investment Plan | May 2026","jir_og_description":"Towa Pharmaceutical announced capital strengthening and amendments to its articles of incorporation, aiming to enhance business expansion and supply stability. A must-see IR update for investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-53622","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n